Neurocrine Biosciences, Inc. (BVMF:N1BI34)

Market Cap	71.38B
Revenue (ttm)	14.30B
Net Income (ttm)	2.28B
Shares Out	n/a
EPS (ttm)	22.34
PE Ratio	31.29
Forward PE	13.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	770
Average Volume	937
Open	36.33
Previous Close	35.49
Day's Range	36.33 - 36.33
52-Week Range	25.64 - 44.95
Beta	0.28
RSI	39.79
Earnings Date	Feb 9, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,800
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: N1BI34

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD